ADC pipelines drive single-use expansion at Lonza's clinical facility

Lonza adding single-use systems at its clinical ADC facility in Visp, Switzerland

Lonza has invested in single-use technology at its Swiss clinical manufacturing facility citing a rise in demand as customer’s grow their antibody-drug conjugate (ADC) pipelines.

The addition of single-use technology at the site in Visp, Switzerland is part of a series of expansions, which include the CHF14m ($15.5m) move to double ADC capacity announced in January 2013, spokesperson Constance Ward told

“This new investment is necessary to continue to support the growing pipeline of novel ADC platforms from our customers by offering them new manufacturing technology with increased throughput,” she said.

For now, the firm is only implementing single-use systems in its clinical ADC manufacturing facility, which makes toxicology lots, early-phase GMP lots and GMP re-supply lots for a number of products currently in clinical trials.

The addition of single-use technology will allow “flexible ADC manufacturing,” Ward told us, whilst reducing potential contamination risks and increasing capacity.

As part of the upgrade, the layout of the plant has been redesigned and the Heating, Ventilation, Air Conditioning (HVAC) systems revamped which, according to the company, has led to a larger ADC production area.

Lonza’s Visp site manufactures Roche’s HER2 breast cancer drug Kadcyla - according to the EMA’s assessment report – and is one of only two ADCs currently approved, by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). The other is Seattle Genetics and Takeda’s Adcetris.

However, whilst Kadcyla is in trials being investigated for additional applications, this latest expansion “is not for any specific product in particular, but to broaden [Lonza’s] offering to all clients with early clinical stage products,” Ward said,

CMO competition

As pharma companies look to develop the latest generation of oncology drugs, there has been a wealth of investments in ADCs by a number of contract manufacturing organisations (CMOs), including Catalent, Piramel and Carbogen Amcis.

However, Ward says in light of CMO competition for ADC services, Lonza has the full range of development tools available from the manufacturing of antibodies, linkers and toxins through to the conjugation of these components.

“Furthermore, Lonza has validated and commercialized leading ADC products [Kadcyla] on a commercial scale,” she added.

Related News

Lonza: stem cell reprogramming makes for better preclinical models

Lonza says stem cell reprogramming makes for better preclinical models

Lonza HQ in Basel, Switzerland

Profits and capacity utilisation up at Lonza in H1 thanks to pharma

Carbogen Amcis has signed a long-term lease for an ADC unit in Vionnaz, Switzerland

Carbogen Amcis takes over Swiss plant to boost ADC offering

CMOs dominate the manufacturing of ADCs though there are only a limited number that can develop linkers and cytotoxins.

Vast majority of ADC manufacturing outsourced, report finds

Antibodies in development

Merck KGaA is latest bi-curious antibody developer in ADC deal with Sutro

Lonza's biologics plant in Portsmouth, US - expanded B-MS deal helped fill capacity

Lonza's biopharma focus intensified towards end of 2014

Lonza to double ADC capacity

Lonza to double ADC capacity to address Visp challenge

Lonza cuts jobs at Visp

Lonza cuts jobs at Visp API and biomanufacturing plant

Lonza ramps up complex manufacturing at Visp

Lonza to boost complex manufacturing at underperforming Visp plant

Lonza says Pharma and restructuiring efforts are on track

Lonza says Pharma business and restructuring efforts are on track

Revenue down but capacity changes looking positive for Lonza

Lonza confident manufacturing capacity will be filled, post Teva biosimilar JV

Lonza's new ADC facility in Visp, Switzerland set to open this quarter

Lonza: growth in mammalian services as ADC plant opening nears

Related Products

See more related products